Status:
UNKNOWN
Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)
Lead Sponsor:
University of Vienna
Conditions:
Type 2 Diabetes
Cancer
Eligibility:
FEMALE
30+ years
Brief Summary
The purpose of the study is to determine whether glycemic control (HbA1c) is linked to chromosomal damage in type 2 Diabetes patients
Eligibility Criteria
Inclusion
- Type 2 Diabetes (T2DM)
- Sex: female
- Age: \> 30years
- Medication: oral anti-diabetics and/or Insulin therapy
- Constant nutritional behavior, constant physical activity, constant weight for the last 4 weeks
- Non-smoking for at least 1 year
Exclusion
- Patients with type 1 DM
- Age: \< 30years
- Pregnant or lactating women
- Participation in another clinical trial
- Change of medication in regard to metabolic parameters within the last 4 weeks
- Significant cardiovascular damage with NYHA \> III
- Liver disease with three-times higher transaminase values
- Chronic kidney disease with serum creatinine \> 2 mg/dl
- Dialysis
- HIV positive
- History of chronic alcohol abuse in the last two years
- History of cancer, stroke, organ transplantation
- Male
Key Trial Info
Start Date :
May 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT02231736
Start Date
May 1 2014
Last Update
September 4 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vienna
Vienna, Austria, 1090